Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosis by Beilong Zhong et al.
Zhong et al. Cancer Cell International 2014, 14:57
http://www.cancerci.com/content/14/1/57PRIMARY RESEARCH Open AccessContribution of nestin positive esophageal
squamous cancer cells on malignant proliferation,
apoptosis, and poor prognosis
Beilong Zhong1†, Tao Wang2,3*†, Xueping Lun4,5,6, Jinli Zhang7, Sannv Zheng8, Weilin Yang4,5,6, Weiqiang Li2,3,
Andy Peng Xiang2,3 and Zhenguang Chen4,5,6*†Abstract
Background: The stem cell-associated intermediate filament nestin has recently been linked with neoplastic
transformation, but the specific mechanism by which nestin positive tumor cells leads to malignant invasion
and metastasis behaviors of esophageal squamous cell carcinoma (ESCC) remains unclear.
Methods: To obtain insight into the biological role of nestin in ESCC, we explored the association of the nestin
phenotype with malignant proliferation and apoptosis in esophageal squamous cancer cells. Nestin expression was
determined in ESCC specimens and cell lines, and correlated with clinicopathological properties, including clinical
prognosis and proliferative markers. The association of the nestin phenotype with apoptotic indicators was also analyzed.
Results: Nestin was expressed in ESCC specimens and cell lines. ESCC patients with nestin-positive tumors had
significantly shorter median survival and progression-free survival times than those with nestin-negative tumors.
Positive staining for the proliferation markers Ki67 and PCNA (proliferating cell nuclear antigen) was detected in
56.9% and 60.2% of ESCC specimens, respectively, and was strongly correlated with the nestin phenotype. Notably,
expression of cyclin dependent kinase-5 (CDK5) and P35 was detected in 53.8% and 48.4% of ESCC specimens,
respectively, and was strongly associated with the nestin phenotype.
Conclusion: Our data demonstrated nestin expression in ESCC specimens and cell lines, and revealed a strong
association of the nestin phenotype with poor prognosis in ESCC patients. Furthermore, we showed that nestin
positive ESCC cells played an important role in the malignant proliferation and apoptosis.
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ApoptosisIntroduction
Esophageal cancer is a malignancy of the esophagus
common throughout the world that is characterized by
its high invasiveness and mortality. Histologically, more
than 90% of esophageal cancers are either esophageal
squamous cell carcinomas (ESCCs) or esophageal adeno-
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unless otherwise stated.histological subtype and accounts for nearly 90% of all
esophageal cancers [1,2]. Despite considerable advance-
ments in surgical techniques and multidisciplinary
treatments based on chemotherapy and radiotherapy,
the overall 5-year survival rate of ESCC patients has
remained low (15%–39%) [3]. The current view is that
the failure of ESCC treatments reflects the frequent
recurrence and metastasis of this cancer type. These
phenomena involve several events, including prolife-
ration and invasion of the primary tumor, sustained
lymphangiogenesis, and evasion of apoptosis; of these
steps, proliferation of the primary tumor appears to be
an integral feature of the molecular and cellular patho-
genesis and metastasis of esophageal cancer [4,5].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mediate filament proteins. Nestin was first identified as
a protein expressed in progenitor cells of the central
and peripheral nervous systems, but has since also been
found in other tissues [6,7]. Notably, it has been proposed
that nestin may be a proliferative and multipotency
potential indicator in several types of progenitor cells
[8-13]. Recent reports have linked nestin with malignant
characteristics in different cancers and suggested that
abundant nestin positive cancer cells correlate with
greater malignancy and poor prognosis [14-17]. We
previously demonstrated that the majority of tumor
cells in non-small cell lung cancer samples are nestin-
positive and showed that nestin expression was posi-
tively correlated with the subset of lung cancer patients
displaying poor outcomes and high levels of prolifera-
tive markers [18,19]. Subsequent studies have revealed
that nestin knockdown inhibits cell proliferation and
G1/S arrest in human non-small cell lung cancer cells,
possibly via downregulation of AKT-GSK3β-cyclin D
signaling. However, the specific function of nestin posi-
tive tumor cells in the invasive and metastatic behaviors
of esophageal cancer remains unclear. Thus, the precise
mechanisms of nestin positive cancer cells action in the
proliferation and metastasis of ESCC require further
elucidation.
In the present study, we sought to characterize the
nestin phenotype in ESCC of Chinese population and
assess its association with esophageal cancer cell prolif-
erative properties and clinical prognosis and patho-
logical parameters. Because no previous studies have
provided detailed information on signaling mechanisms
involved in the proliferation of esophageal cancer cells
relevant to the nestin phenotype, we further investi-
gated the mechanism underlying this linkage.
Materials and methods
Tissue specimens
A total of 93 ESCC samples were randomly selected from
our tissue database. Samples were obtained from patients
treated in the Department of Thoracic Surgery from the
First Affiliated Hospital of Sun Yat-sen University between
September 2005 and March 2009. The selection criteria
included: 1) all cases were confirmed by histopathology; 2)
all cases were performed the esophagectomy treatment; 3)
at least six lymph nodes were examined for pathological
diagnosis; 4) none of the patients had received neoad-
juvant chemotherapy or radiotherapy. Clinical infor-
mation was obtained by reviewing preoperative and
perioperative medical records or via telephone or written
correspondence. Cases were staged based on the tumor-
node-metastasis (TNM) classification of the International
Union Against Cancer, revised in 2002 [20,21]. The use of
human materials was approved by the Medical EthicalCommittee of The First Affiliated Hospital, Sun Yat-sen
University (No. 2008–7). Clinical characteristics of
patients were shown in Table 1.
Cell lines
The esophageal squamous cell cancer cell lines, Eca-109
and TE-1, were obtained from the Cell Bank of the
Chinese Academy of Sciences (Shanghai, China), and
cultured according to the specific cell bank protocol.
Immunohistochemical staining
The immunohistochemical procedure was similar to
previously reported protocols [18,19,22]. Anti-nestin
(AB5922; Millipore, Temecula, CA, USA; 1:500 dilu-
tion), anti-Ki-67 (SC-15402; Santa Cruz Biotechnology,
Santa Cruz, CA, USA; 1:500 dilution), anti-PCNA
(PC10; Cell Signaling Technology, Danvers, MA, USA;
1:4000 dilution), anti-CDK5 (SC-6247; Santa Cruz
Biotechnology; 1:1000 dilution), and P35 (SC-820; Santa
Cruz Biotechnology; 1:400 dilution) were used as primary
antibodies. Ki67 and PCNA staining in ESCC tissue
samples was quantified with an optical density-based
method using Image-Pro plus 6.0 software (Media
Cybernetics, Inc.; Rockville, MD, USA). Double staining
of nestin and Ki-67 or nestin and PCNA were processed
using strept avidin-biotin complex (SABC) reagent
(MXB, KIT-9999, China) and biotinylated antibody was
used as secondary antibody [23].
RT-PCR analysis
Total RNA was extracted, and amplified by reverse
transcription-polymerase chain reaction (RT-PCR) using
the following primer pairs: nestin, 5’-GAG GAC CAG
AGT ATT GTG AGA C-3’ and 5’-CAC AGT GGT GCT
TGA GTT TC-3 (368 bp); and β-actin (internal control),
5’-GTG GGG CGC CCC AGG CAC CA-3 and 5-CTC
CTT AAT GTC ACG CAC GAT TTC-3’ (540 bp).
Immunoblotting analysis
Proteins were separated, electrotransferred to polyviny-
lidene difluoride (PVDF) membranes, blocked with a
solution of Tris-buffered saline containing 0.1% Tween-
20 (TBST), incubated with mouse anti-nestin antibody
(AB5922; Millipore; 1:500 dilution) overnight, and
detected with a horseradish peroxidase-conjugated anti-
mouse secondary antibody (Cell Signaling Technology).
An anti-GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) antibody (SC-81545; Santa Cruz Biotechnology)
was used as an internal control.
Statistical analysis
All calculations were performed using SPSS V.14.0 stat-
istical software (Chicago, IL, USA). T-tests, Pearson’s and
Spearman's coefficient of correlation, logistic regression,
Table 1 Association of nestin expression with clinicopathological features in ESCC
Characteristics No. of patients Nestin expression n (%) P-value*
Positive Negative
Gender Male 72 24 (33.3) 48 (66.7) 0.686
Female 21 8 (38.1) 13 (61.9)
Age (y) ≤60 51 16 (31.4) 35 (68.6) 0.497
>60 42 16 (38.1) 26 (61.9)
Differentiation Poor 32 6 (18.7) 26 (81.3) 0.070
Moderate 44 19 (43.2) 25 (56.8)
Well 17 7 (41.2) 10 (58.8)
TNM stage I 5 1 (20) 4 (80) 0.133
II 56 23 (41.1) 33 (58.9)
III + IV 32 9 (30.8) 23 (69.2)
Lymph nodes Positive 34 9 (26.5) 25 (73.5) 0.221
Negative 59 23 (39.0) 36 (61.0)
Ki67 expression Positive 53 23 (43.4) 30 (56.6) 0.036
Negative 40 9 (22.5) 31 (77.5)
PCNA expression Positive 56 26 (46.4) 30 (53.6) 0.003
Negative 37 6 (16.2) 31 (83.8)
CDK5 expression Positive 50 23 (46.0) 27 (54.0) 0.022
Negative 43 10 (23.3) 33 (76.7)
P35 expression Positive 45 24 (53.3) 21 (46.7) 0.031
Negative 48 15 (31.2) 33 (68.8)
*Chi-square test.
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survival time (MST) and progression-free survival time
(PFS) were calculated from the date of surgery until the
date of tumor recurrence and last follow-up, and the
association of nestin expression with MST and PFS was
presented as Kaplan-Meier plots. Univariate and multi-
variate analyses were performed using Cox proportional
hazards regression to determine the prognostic effects
of nestin expression and potential clinical variables on
MST and PFS.
Results
Basic clinical information and follow-up studies
In total, 72 male and 21 female patients with esophageal
cancer subjected to curative surgical resection were en-
rolled in the study. The mean age of patients was 60.96 ±
9.98 years (range, 38 to 86 years). All cases were esopha-
geal squamous cell cancer. Cases were classified as
stage I (n = 5), stage II (n = 56), stage III (n = 28) and
stage IV (n = 4), and categorized according to differen-
tiation status as poor (n = 32), intermediate (n = 44),
and well differentiated (n = 17). Patient data were ana-
lyzed after 5-years of follow-up, and information was
obtained for 94.6% (88 of 93) of patients. Pathological
characteristics of patients are shown in Table 1.Nestin expression in ESCC tissue specimens
Using immunohistochemical scoring methods and op-
tical density statistical software, we estimated nestin
antibody staining results qualitatively and quantita-
tively. Among all tissue specimens, 32 cases (34.4%)
were nestin positive (Figure 1A and B) and 61 cases
(65.6%) were nestin negative (Figure 1C and D). Regarding
to the heterogeneity of nestin staining intensity, the mean
optical density was 0.141 (minimum: 0.090; maximum:
0.231) in positive cases and was 0.042 (minimum:
0.002; maximum: 0.089) in negative cases. As shown in
Figure 1, nestin expression in tumor cells was detected
in both the cytoplasm and nucleus.
Nestin expression in ESCC cell lines
To further examine the expression status of nestin in
ESCC, we examined its expression patterns in the ESCC
cell lines, Eca-109 and TE-1. Nestin mRNA and protein
were detected in both cell lines (Figure 2A and B).
Association of nestin expression with poor prognosis in
ESCC patients
The baseline characteristics of the study population
with regard to the nestin phenotype and the results of
multivariate analyses are presented in Tables 1 and 2,
Figure 1 Nestin expression in the cytoplasm and nucleus of ESCC specimens. (A and B) Nestin-positive staining; (C and D) weak or negative
nestin staining (Scale bar, 100 μm).
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was 15.2 ± 4.2 months (95% CI: 13.3 - 16.7 months).
Considering subpopulations based on nestin expres-
sion status, the MST of nestin-positive patients (8.3 ±
2.4 months, 95% CI: 5.7 – 10.3 months) was signifi-
cantly shorter than that of nestin-negative patients
(16.0 ± 5.34 months, 95% CI: 14.9 - 17.1 months; P =
0.023; Figure 3A). PFS for the entire study population
was 12.4 ± 3.9 months (95% CI: 10.4 - 4.4 months). As
was the case for MST, PFS was significantly shorter for
nestin-positive patients (9.3 ± 3.0 months, 95% CI: 6.6 -
11.9 months) than for nestin-negative patients (14.0 ±
4.1 months, 95% CI: 11.4 - 16.7 months; P = 0.005;
Figure 3B). A multivariate statistical analysis (Table 2)
showed that nestin was a significant prognostic indi-
cator independent of other clinical and pathological
factors (HR: 1.586; P = 0.047).Figure 2 Nestin mRNA and protein expression in Eca-109 and
TE-1 ESCC cell lines detected by RT-PCR (A) and immunoblotting
analysis (B).Association of nestin with tumor cell proliferative markers
Expression of the proliferative markers Ki67 and PCNA
in ESCC tissue samples was determined by immunohis-
tochemical staining. Of the 93 cases of ESCC, 53 (56.9%)
were positive for the expression of Ki67, which was
mainly nuclear (Figure 4A), and 40 (43.1%) were negative
for Ki67 expression (Figure 4B). Similar results were ob-
tained for the expression of PCNA; in 56 cases (60.2%),
cells were positive for PCNA expression (Figure 4C)
and in 37 cases (43.1%), cells were negative for PCNA
expression (Figure 4D). As expected, PCNA expression
was mainly detected in ESCC nuclei (Figure 4C). Ki67
and PCNA expression was quantified (Table 3) using an
optical density scoring method employing image analysis
software (see Materials and Methods). As shown in
Figure 5 (A and B) and Table 1, a subsequent Pearson’s
correlation analysis revealed a significant relationship be-
tween the nestin phenotype and Ki67 and PCNA optical
density (Ki67: r = 0.223, P = 0.036; PCNA: r = 0.328, P =
0.003). As shown in Figure 6, double staining of nestin
and Ki-67 or nestin and PCNA was performed and re-
vealed the status of proliferation of nestin-positive cells.
Association of nestin with tumor cell apoptotic markers
As a first step toward identifying the signaling pathway
underlying the nestin phenotype, we assessed the expres-
sion of P35 and CDK5 (cyclin-dependent kinase 5),
which is regulated by P35, in ESCC specimens. Of the
93 samples, 50 (53.8%) were positive for CDK5 and 45
(48.4%) were positive for P35 (Figure 4). CDK5 and P35
expression were detected in both nuclei and cytoplasm
of ESCC cells. As shown in Figure 5, an analysis of the
Table 2 Univariate and multivariate analyses of nestin expression in relation to median survival time of ESCC patients
Variable Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Nestin expression
Positive 1.579 1.025–2.432 0.038 1.586 1.007–2.499 0.047
Negative 1.000 1.000
Differentiation
Poor 0.680 0.442–1.049 0.081 0.658 0.412–1.053 0.080
Moderate and well 1.000 1.000
TNM classification
III + IV 1.268 0.820–1.961 0.286 0.862 0.201–3.692 0.842
I + II 1.000 1.000
Sex
Male 1.181 0.716–1.946 0.515 1.397 0.826–2.363 0.212
Female 1.000 1.000
Age
≥60 years 0.881 0.582–1.334 0.550 0.755 0.486–1.172 0.210
<60 years 1.000 1.000
Lymph nodes metastasis
With 1.330 0.864–2.048 0.195 1.870 0.451–7.757 0.388
Without 1.000 1.000
Abbreviations: HR hazard ratio; LN lymph nodes.
*Chi-square test.
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http://www.cancerci.com/content/14/1/57relationship between CDK5 and P35 expression, quanti-
fied using an optical density-based scoring method
(Table 3), and the nestin phenotype revealed a significant
Pearson’s correlation coefficient (CDK5: r = 0.240, P =
0.022; P35: r = 0.261, P = 0.031).Figure 3 Kaplan-Meier plot depicting the differences in MST (A) and P
dichotomized based on the median value of nestin expression in tumDiscussion
Nestin was initially discovered based on its expression
in neural progenitor cells, where it was considered a
marker for distinguishing precursor cells from differenti-
ated cells [24,25]. Subsequent reports have shown thatFS (B) between nestin-positive and -negative groups,
or lesions. *P < 0.05 (ANOVA).
Figure 4 Strong (A) and weak (B) Ki67 staining in ESCC specimens; strong (C) and weak (D) PCNA staining in ESCC specimens; strong
(E) and weak (F) CDK5 staining in ESCC specimens; strong (G) and weak (H) P35 staining in ESCC specimens (Scale bar, 100 μm).
Table 3 Association of nestin expression with Ki67, PCNA,
CDK5 and P35 expression, determined using an optical
density method
Nestin-positive Nestin-negative P-value*
Ki67 0.0124 ± 0.0033 0.0057 ± 0.0010 <0.0001
PCNA 0.1318 ± 0.0060 0.0831 ± 0.0052 <0.001
CDK5 0.2609 ± 0.0120 0.2140 ± 0.0053 <0.001
P35 0.2050 ± 0.0118 0.1478 ± 0.0100 <0.0001
*Chi-square test.
Zhong et al. Cancer Cell International 2014, 14:57 Page 6 of 10
http://www.cancerci.com/content/14/1/57nestin is expressed in breast, prostate and pancreatic
cancer, and is positively correlated with tumor malig-
nancy [15,26,27]. Sustained expression of nestin in
spindle cells or epithelial cells of esophageal leiomyoma
has also been reported [28]. However, no studies have
examined nestin expression in ESCC.
Here, we first established that nestin is expressed in
34.4% of ESCC samples in Chinese population, a result
similar to that reported for lung squamous cell carcinoma
(35.5%) and our previous findings in NSCLC [19,29].
Consistent with these findings, we also detected nestin
mRNA and protein in the ESCC cell lines, Eca-109 and
TE-1.
Figure 5 Significant correlation of nestin expression levels with (A) Ki67 expression levels (r = 0.223; P < 0.05), (B) PCNA expression
levels (r = 0.328; P < 0.05), (C) CDK5 expression levels (r = 0.240; P < 0.05), and (D) P35 expression levels (r = 0.223261; P < 0.05). Each
point represents one ESCC specimen.
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significantly associated with poor prognosis in Chinese
patients with ESCC. Some studies have reported that
nestin expression in vascular sarcoma, pancreatic can-
cer, and gastrointestinal stromal tumors is closely
correlated with the degree of malignancy and patient
prognosis [14,15,30]. In our study, we found significant
differences in both MST and PFS between patients in
nestin-positive and nestin-negative groups. Further-
more, a multivariate statistical analysis showed that
nestin was a significant prognostic indicator independent
of other clinical and pathological factors. Therefore, our
experiments showed that Chinese ESCC patients with
nestin-positive tumors had a worse prognosis than those
in the nestin-negative group.
Thirdly, we found that the nestin phenotype of ESCC
cells was closely related to malignant proliferation.Recent studies have reported that tumor cells with high
expression of nestin show rapid proliferation [31]. In
our experiments, we used Ki67 and PCNA as prolifera-
tive markers. Ki67, a nuclear protein that has been
widely used in tumor biology as a marker of tumor-cell
proliferation, plays an important role in regulating cell
differentiation [32]. PCNA, a trimer that forms a clamp
around DNA and promotes DNA polymerase-dependent
DNA replication, is highly expressed in proliferating cells,
especially tumor cells; in the latter, high expression of
PCNA is correlated with high malignancy [33-35]. Among
ESCC clinical specimens, 56.9% and 60.2% were positive
for Ki67 and PCNA, respectively. Moreover, a quantitative
analysis revealed that Ki67 and PCNA expression were
positively correlated with nestin expression. Taken
together, these findings indicate that the nestin phenotype
is positively correlated with ESCC cell proliferation,
Figure 6 Significant double staining of nestin and Ki67 was
shown in A and B. Red color indicated nestin staining and black
color indicated Ki67 staining. Meanwhile, strong double staining of
nestin and PCNA was shown in C and D. Red color indicated nestin
staining and black color indicated PCNA staining (Scale bar, 100 μm).
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regulating ESCC cell proliferation.
We also investigated possible association of nestin
with tumor cells apoptosis by examining the expression
of CDK5 and P35 using immunohistochemistry. CDK5
is a member of the cyclin-dependent kinase family that
is preferentially expressed in terminally differentiated
cells, such as neurons, muscle, and lens fibers [36-40].
CDK5 activity is mainly regulated by its association with
P35 (which is often, but not exclusively, associated with
neural tissues) and to lesser degree by P39 [40]. CDK5 is
able to perform substrate phosphorylation in different
cellular compartments, including the cytoplasm and nu-
cleus [41,42]. Some reports suggest that CDK5 may have
a significant role in the regulation of breast, lung, and
prostate cancer cell proliferation, apoptosis, migration,
and invasion [43-45]. We found that 53.8% and 48.4% of
ESCC cases were positive for the expression of CDK5
and P35 expression, respectively; CDK5 and P35 were
detected in both nuclei and cytoplasm, consistent with
a previous report [46]. Importantly, CDK5 and P35 ex-
pression were positively correlated with nestin expres-
sion, suggesting the possibility that nestin promotes
ESCC cell apoptosis. In this latter context, it is con-
ceivable that nestin might serve as a nuclear scaffoldfor CDK5 that could affect the organization, stability,
and activity of the CDK5 and P35 signaling complex,
as suggested by the reported importance of nuclear
localization in the activity of Cdk5 [42,47].
Based on the data that the nestin phenotype is closely
correlated with ESCC cell proliferation and apoptosis, by
extension, our results suggest an association with metas-
tasis, consistent with recent reports that tumor cells with
high expression of nestin more readily metastasize.
Metastasis is a gradual and complex process that re-
quires a collection of dispersed tumor cells with sev-
eral capabilities, including invasion into the circulatory
system from the primary tumor, survival in the circula-
tion, exudation at a distant site, and proliferation in an
alien and inhospitable environment [47,48]. The ability
of tumor cells to migrate and invade into the circula-
tory system from the primary tumor is related to tumor
cell motility. Cell motility is important during embry-
onic development as well as in physiological processes
of many adult organs. This kind of motility is regulated
by numerous mechanisms, including a link between
the epithelial cell membrane and the cytoskeleton. One
such mechanism is that mediated by intermediate fila-
ments. For example, cytoskeletal reorganization of
actin filaments is very important for cell motility and
also underlies most cell migration [47,48]. As a mem-
ber of the class VI family of intermediate filament pro-
teins and a cytoskeletal element, nestin has an effect in
tumor cells similar to that of actin. When tumor cells
successfully invade the circulatory system from the ori-
ginal tumor and reach an alien immune-surveillance
environment, their ability to survive—largely a reflec-
tion of their ability to proliferate—becomes the key to
their successful metastasis in this environment. In our
experiments, nestin expression in ESCC samples was
positively correlated with Ki67 and PCNA expression,
predicting that nestin-positive esophageal squamous
cells would proliferate more rapidly than nestin-
negative cells. We also found that MST and PFS of
nestin-positive ESCC patients were shorter than those
of nestin-negative patients. The current view is that
the primary reasons for the failure of ESCC surgical
treatments are recurrence and metastasis [4]. Our pre-
liminary studies demonstrating that nestin expression
is positively correlated with the proliferative and apop-
totic behavior of ESCC provide a possible explanation
for the prognostic value of nestin. Collectively, our
findings demonstrate that nestin-expressing tumor
cells are important for proliferation, apoptosis, migra-
tion, and metastasis in ESCC.
While our results suggest that nestin contributes to
the proliferation and apoptosis in ESCC cells, other
aspects of metastasis, such as angiogenesis, lymphan-
giogenesis and tumor metabolism, were not directly
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nestin needs to be considered in clinical diagnosis and
as a potential new target for cancer therapy.
In summary, we observed nestin-positive tumor cells
in a portion of ESCC samples in Chinese population and
demonstrated a significant association of nestin expres-
sion with the subset of Chinese ESCC patients displaying
poor outcomes and high levels of proliferative markers.
Our preliminary findings of positive correlations be-
tween nestin expression and CDK5 and P35 expression
further support the tentative conclusion that nestin
likely promotes ESCC cell apoptosis. Collectively, our
data suggest that tumor cells expressing nestin promote
ESCC cell proliferation and apoptosis, which may consti-
tute a key mechanism of nestin-mediated metastasis in
esophageal cancer cells. Targeted regulation of nestin
may thus have therapeutic applications in the treatment
of human esophageal cancer.
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